RxDoctor Payments DataLook up a doctor →

Mark Purcell, DO

Internal Medicine · Greenville, SCNPI 1639183544

Payments from drug & device makers

$164,709in general payments, 2019–2025

Across 565 payments — averaging $291.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$82K
  • Lilly USA, LLC$43K
  • Boehringer Ingelheim$32K
  • Johnson & Johnson$1K
  • Amgen$1K
  • Novartis$526
  • plus $4K from 23 others

What the payments were for

  • Consulting fees$3750%
  • Speaking & faculty fees$145,22088%
  • Travel & lodging$9,0616%
  • Food & beverage$9,8106%
  • Education$2440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$164,709 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$200,672
Medicare patients
638
Services billed
2,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol249$190,093
JardianceEmpagliflozin130$117,458
KerendiaFinerenone42$27,437
VeltassaPatiromer Calcium Sorbitex23$19,994
Sevelamer Carbonate17$2,461
Calcium Acetate24$2,142
Bumetanide30$936
Nifedipine ErNifedipine33$930
Gentamicin Sulfate24$866
Calcitriol56$594
Amlodipine Besylate93$544
Torsemide38$492
Labetalol Hcl13$454
Hydralazine Hcl29$438
Losartan Potassium65$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$82,171$190,093249 claims
Boehringer IngelheimJardiance$32,170$117,458130 claims
BayerKerendia$470$27,43742 claims
ANI Pharmaceuticals, Inc.Valsartan$79$12711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →